A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population

April 11, 2022
poster for A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population
Eliza Anderson, PharmD
Karen Stevens, PharmD
Commonwealth Medicine
Rachel Bacon, PharmD
Commonwealth Medicine
Stephanie Tran, PharmD, BCPS
University of Massachusetts Medical School
Caroline J. Alper, MD
Commonwealth Medicine
Thomas Pomfret, PharmD, MPH, BCPS
Commonwealth Medicine
Karen Clements, ScD
Commonwealth Medicine
Pavel Lavitas, PharmD, BCPS
Commonwealth Medicine
Kimberly Lenz, PharmD, MBA, FAMCP
Commonwealth Medicine

Asthma is a common disease-state that has a high societal cost, especially in the treatment of severe asthma. This research evaluated whether the initiation of dupilumab, a biologic indicated for asthma, reduced asthma-related emergency department visits or hospitalizations, the number of asthma rescue medications used, and the total cost of asthma-related exacerbations among MassHealth members. The data showed a reduction in emergency department visits and hospitalizations as well as the number of asthma rescue medications used; however, these findings were not statistically significant.  

A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population